Money Control Place
  • Politics
  • Business
  • Stocks
  • Investing
  • Politics
  • Business
  • Stocks
  • Investing

Money Control Place

Business

Pfizer CEO says tariff uncertainty is deterring further U.S. investment in manufacturing, R&D

by admin April 30, 2025
April 30, 2025
Pfizer CEO says tariff uncertainty is deterring further U.S. investment in manufacturing, R&D

Pfizer CEO Albert Bourla on Tuesday said uncertainty around President Donald Trump’s planned pharmaceutical tariffs is deterring the company from further investing in U.S. manufacturing and research and development. 

Bourla’s remarks on the company’s first-quarter earnings call came in response to a question about what Pfizer wants to see from tariff negotiations that would push the company to increase investments in the U.S. It comes as drugmakers brace for Trump’s levies on pharmaceuticals imported into the country — his administration’s bid to boost domestic manufacturing.

“If I know that there will not be tariffs … then there are tremendous investments that can happen in this country, both in R&D and manufacturing,” Bourla said on the call, adding that the company is also hoping for “certainty.”

“In periods of uncertainty, everybody is controlling their cost as we are doing, and then is very frugal with their investment, as we are doing, so that we are prepared for remit. So that’s what I want to see,” Bourla said.

Bourla noted the tax environment, which had previously pushed manufacturing abroad, has “significantly changed now” with the establishment of a global minimum tax of around 15%. He said that shift hasn’t necessarily made the U.S. more attractive, saying “it’s not as good” to invest here without additional incentives or clarity around tariffs.

“Now [Trump] I’m sure — and I know because I talked to him — that he would like to see even a reduction in the current tax regime particularly for locally produced goods,” Bourla said, adding a further decrease would be would be a strong incentive for manufacturing in the U.S.

Unlike other companies grappling with evolving trade policy, Pfizer did not revise its full-year outlook on Tuesday. However, the company noted in its earnings release that the guidance “does not currently include any potential impact related to future tariffs and trade policy changes, which we are unable to predict at this time.”

But on the earnings call on Tuesday, Pfizer executives said the guidance does reflect $150 million in costs from Trump’s existing tariffs.

“Included in our guidance that we didn’t really speak about is there are some tariffs in place today,” Pfizer CFO Dave Denton said on the call.

“We are contemplating that within our guidance range and we continue to again trend to the top end of our guidance range even with those costs to be incurred this year,” he said.

This post appeared first on NBC NEWS

0
FacebookTwitterGoogle +Pinterest
previous post
The Best Five Sectors, #17
next post
Charbone Hydrogen Announces 2024 Financial Results

Related Posts

Collapsed crypto exchange Mt. Gox is about to...

July 3, 2024

Bud Light sales plunged after boycott over campaign...

August 4, 2023

Tesla investors want Elon Musk to answer questions...

January 30, 2025

Starbucks to face lawsuit alleging its Refresher fruit...

September 22, 2023

Restaurants are rebounding — but Starbucks and McDonald’s...

January 30, 2025

Costco sold more than $100 million in gold...

December 16, 2023

Here’s how Starbucks plans to improve its stores

July 2, 2024

Titanic submersible lost at sea raises legal questions...

June 22, 2023

JPMorgan CEO Jamie Dimon hopes for soft landing...

April 30, 2024

UAW and Ford reach tentative agreement, potentially ending...

October 29, 2023

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    • Emerging Stocks to Watch – Breakouts, Momentum & Upgrades!

    • S&P 500, Bitcoin & XLK: What the Charts Are Saying Now

    • Metals Focus: PGMs Deficits Deepen as Supply Tightens and Demand Realigns

    • 5 Small-cap Biotech ETFs to Watch

    • Canaccord Global Mining Conference Presentation

    • Anteros Identifies High-Grade Copper-Gold Targets at the Strickland VMS Property, Newfoundland

    Categories

    • Business (1,204)
    • Investing (2,459)
    • Politics (3,699)
    • Stocks (1,587)
    • Uncategorized (20)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: MoneyControlPlace.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 moneycontrolplace.com | All Rights Reserved